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Abstract
Background: Time-dependent chemotherapeutic agents can selectively target tumor cells in susceptible phases of
the cell cycle however a fraction of tumor cells in non-vulnerable cell cycle phases remain drug-resistant.
Immunotherapy represents a promising approach to overcome the limitation of phase-specific drugs and improve
their clinical efficacy. Here, we investigated the potential use of anticancer chemotherapeutic drugs in combination
with IL-18, a cytokine with strong immunostimulatory properties.
Methods: Four chemotherapeutic drugs commonly used in ovarian cancer were first tested for the ability to
increase the immunogenicity and killing of the murine ovarian cancer cell line ID8 in vitro. Chemotherapeutric
agents with measured time-dependent immune-enhancing effects were then tested for antitumor effectiveness in
vivo in combination with IL-18 immunotherapy using the ID8-Vegf ovarian cancer model.
Results: Paclitaxel or topotecan exposure alone mediated incomplete, time-dependent killing against the murine
ovarian cancer cell line ID8 in vitro, whereas carboplatin or gemcitabine mediated comprehensive, dose-dependent
killing. In the plateau phase of the time-dependent killing by topotecan or paclitaxel, drug-resistant ID8 cells were
more immunogenic with elevated expression of MHC-I and Fas, and increased sensitivity to CTL and Fas agonistic
antibody in vitro. Moreover, the antitumor effectiveness of time-dependent agents in vivo was significantly
improved with the addition of IL-18 through a T cell-dependent mechanism, while the effectiveness of drugs
without significant phase specificity were not.
Conclusions: Tumor immunotherapy with IL-18 can significantly augment the killing fraction of phase-specific
chemotherapeutic drugs and provide survival benefit. The safety profile of IL-18 and its positive interactions with
select anticancer chemotherapeutic agents strongly supports the clinical investigation of this combinatorial
approach.
Background
Although chemotherapy is the treatment of choice for
many types of cancer, it is rarely curative in most solid
tumors. Immune therapy represents a potentially attrac-
tive approach to increase the efficacy of chemotherapy
by targeting cancer cells that escape chemotherapy.
However, it has been unclear to date whether any che-
motherapy drugs are more suitable than others for such
combinations, and empirical use has produced mixed
results. For example, although higher objective response
and disease control rates, along with elevated frequen-
cies of cytolytic tumor antigen-specific T cells, were
seen in patients with metastatic colorectal carcinoma
receiving polychemotherapy with gemcitabine plus oxali-
platin, fluorouracil, and folinic acid (FOLFOX-4) fol-
lowed by granulocyte-macrophage colony-stimulating
factor (GM-CSF) and low-dose interleukin-2 (IL-2) [1],
addition of IL-2 and interferon-alpha2b did not increase
the efficacy of cisplatin, vindesine and dacarbazine in
melanoma patients [2]. Thus, understanding the
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apy interactions is a critical task for the development of
effective cancer therapy.
Previous reports have suggested that the exposure of
tumor cells to chemotherapeutic drugs can sensitize
them to immune effector cells [3-6]. Theoretically, to
achieve synergy with immune therapy and increased
tumor killing, chemotherapy should sensitize to immune
killing tumor cells that are destined to survive che-
motherapy. Depending on their mechanism of action,
the efficacy of chemotherapy drugs may be influenced
markedly by the time of exposure (phase-specific or
time-dependent drugs) or by the dose that can be admi-
nistered (phase-nonspecific or dose-dependent drugs).
The efficacy of phase-specific anticancer drugs is time-
dependent, as only a fraction of tumor cells are in
appropriate cell cycle phase for chemotherapy-mediated
killing at any given time. Thus, a fraction of tumor cells
remains alive following administration of each che-
motherapy dose and can eventually repopulate the
tumor following completion of chemotherapy [7-10].
We hypothesized that because of this property, time-
dependent chemotherapy drugs are more likely to bene-
fit from combination with immune therapy.
Interleukin 18 (IL-18) is a pleiotropic cytokine, origin-
ally described as interferon (IFN)-g inducing factor, that
can mediate immunostimulatory effects on immune
cells of the adaptive and innate immune system [11]. Its
multiple immunologic activities include the induction of
IFN-g,T N F - a,I L - 1 a,a n dG M - C S Fp r o d u c t i o n ;a u g -
mentation of natural killer (NK) cell cytotoxicity; and
promotion of Th1 differentiation of naive T cells. These
features render IL-18 an interesting candidate for tumor
immunotherapy. As a single agent, IL-18 was shown to
elicit anti-tumor reactivity when administered at high
doses in mice with established tumors [12]. The immu-
nostimulatory activity of IL-18 in vivo has been demon-
strated in non-human primates [13] and humans [14].
In phase I clinical evaluation, recombinant human (rh)
IL-18 was safely administered as monotherapy to 28
patients with solid tumors, with minimal dose-limiting
toxicities and two partial tumor responses [14]. Toxicity
has generally been mild to moderate even with repeat
administration and a maximum tolerated dose has not
been reached to date [15]. IL-18 enhanced activation of
peripheral blood CD8
+ T cells, NK cells and monocytes
and induced a transient increase in the frequency
and expression level of Fas ligand (FasL) in peripheral
blood CD8
+ T cells and NK cells [15]. The relatively
minor toxicity of rhIL-18, compared with other immu-
nostimulatory cytokines that have undergone clinical
development, is remarkable and renders IL-18 a well
suited drug for combinatorial approaches with
chemotherapy.
In the current study, we characterized the immune
effects on tumor cells of four common anticancer che-
motherapy drugs utilized in ovarian cancer and other
solid tumors, two phase-specific (time-dependent) drugs,
paclitaxel and topotecan, and two phase-nonspecific
(dose-dependent) drugs, gemcitabine and carboplatin.
Both paclitaxel and topotecan exert their actions on
dividing cells, acting as phase-specific chemotherapeutic
drugs. Paclitaxel inhibits the dissolution of microtubules,
enhances tubulin polymerization and produces a block
in the metaphase of mitosis, leading to growth inhibition
and cell apoptosis [16]. Topotecan, a topoisomerase I
inhibitor, stabilizes the covalent complex of enzyme and
strand-cleaved DNA, which is an intermediate of the
catalytic mechanism, thereby inducing breaks in the
protein-associated DNA single-strands, resulting in cell
death [17]. Carboplatin is a classic cycle phase non-spe-
cific drug [18]. The main mechanism of action of gemci-
tabine is inhibition of DNA synthesis. The killing effects
of gemcitabine are however not confined to the S-phase
of the cell cycle and the drug is equally effective against
confluent cells and cells in log-phase growth [19]. Incor-
poration of gemcitabine into RNA is another action,
which is time- and concentration-dependent and leads
to inhibition of RNA synthesis. In human tumor cell
lines displaying different degrees of resistance to gemci-
tabine, sensitivity to this drug was related to differences
in RNA incorporation [20]. Moreover, several metabo-
lites of gemcitabine can inhibit various enzymes, leading
to self-potentation of gemcitabine action [21]. Thus, the
overall mechanism of action of gemcitabine is phase
non-specific.
Because the effect of immune therapy becomes clini-
cally relevant only if immune mechanisms target the
tumor fraction surviving chemotherapy, we focused on
the fate of tumor cells escaping direct killing by che-
motherapy. We hypothesized that these cells are sensi-
tized to immune therapy, which enables a cooperation
between immunotherapy and time-dependent (phase-
specific) drugs. Thus, we hypothesized that among che-
motherapy drugs, time-dependent (phase-specific) drugs
are more likely to benefit from IL-18 therapy combina-
tion. We investigated these interactions in a mouse
model of ovarian cancer [22]. IL-18 alone had a modest
antitumor effect, while it exhibited positive interaction
with select chemotherapeutic drugs, improving their
therapeutic effect in vivo. Chemotherapeutic agents
upregulated immune molecules in tumor cells and sensi-
tized them to immune-mediated killing. Importantly,
this effect was translated to a significant increase in
total killing fraction and better outcome only for time-
dependent drugs. Interestingly, combination of IL-18
with dose-dependent drugs did not increase their effi-
cacy in vivo. In this study however we sought to mainly
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more susceptible to immunotherapy with IL-18, and
specifically focused on effector mechanisms, and not the
drugs’ overall effects on the immune system. Moreover,
our findings indicate for the first time that the differ-
ence of chemotherapeutic drugs in their ability to inter-
act with immunotherapy might be attributed to their
mechanism of action directly on the tumor cell. These
data suggest that tumor immunotherapy with IL-18 may
potentiate the antitumor effect selectively of time-
dependent chemotherapeutics used in various types of
cancer.
Methods
Cell Culture and Reagents
ID8 ovarian cancer cells were generously donated by
Drs. Kathy Robby and Paul Terranova (Kansas Univer-
sity) [23]. The development and characterization of ID8-
Vegf cell line was described elsewhere in detail [22].
The development and characterization of the ID8-E6E7
cell line transfected to stably express the E6 and E7
genes of the human papilloma virus was described else-
where in detail [24]. Briefly, ID8 cells were transduced
with the retroviral vector LXSN16E6E7 (American Type
Culture Collection, Rockville, MD, donated by Dr. D.
Galloway), which encodes the HPV16 E6 and E7 genes,
as well as the neomycin phosphotransferase gene. The
PA317 cell line was used to generate the retroviral vec-
tors as previously described [25]. Selection of ID8 cells
transduced with E6 and E7 (ID8-E6/7) or ID8 cells
transduced with a control retroviral vector (LXSN) was
achieved under neomycin pressure (1mg/ml). ID8, ID8-
E6E7 and ID8-Vegf cells were maintained in DMEM
media (Invitrogen, Carlsbad, CA) supplemented with
10% fetal bovine serum (FBS), 100 U/ml penicillin, and
100 μg/ml streptomycin (Roche, Indianapolis, IN) in a
5% CO2 atmosphere at 37°C. ID8-Vegf cells were used
for in vivo experiments. ID8 cells were used for in vitro
and flow cytometry experiments. ID8-E6E7 cells were
used as target cells for cytotoxicity assays. All reagents
were from Sigma unless stated otherwise.
Mice and Treatments
Eight to sixteen week old female C57BL/6 mice and
C57BL/6 severe combined immunodeficient (SCID)
mice (Charles River Laboratories, Wilmington, MA)
were used in protocols approved by the Institutional
Review Board of the University of Pennsylvania. Mice
were treated with intraperitoneal (i.p.) bolus injections
of chemotherapy drugs or PBS (controls) as follows:
Carboplatin, 20 mg/kg in 0.2 ml 0.9% saline, four weekly
doses; paclitaxel, 15 mg/kg in 0.3 ml 0.9% saline, four
weekly doses; topotecan, 2.5 mg/kg in 0.2 ml 0.9% sal-
ine, every 5 days (total five doses); and gemcitabine,
25mg/kg in 0.2ml 0.9% saline, every 3 days (total five
doses). Chemotherapy doses were approximately one-
fourth to one-sixth of the respective maximally tolerated
dose (MTD) for mice [26-30]. Recombinant murine
(rm)IL-18 (GlaxoSmithKline) was given s.c daily for 40
days at 10 μg/mouse in 90 μl PBS. Control mice
received s.c. daily injections of PBS (100 μl) alone. Che-
motherapy administration was started 8 days after
tumor inoculation and IL-18 treatment was started two
days later.
Tumors
Orthotopic intraperitoneal (i.p.) tumors were generated
by inoculating intraperitoneally 5 × 10
6 ID8-Vegf cells
suspended in 250 μl PBS. Mice were weighed weekly
starting two weeks after tumor inoculation. Ascites
volume measurement was a terminal procedure and it
was done when mice reached 35 grams of weight. When
we needed week-to-week measurements of ascites accu-
mulation, we used weight increase as surrogate. Solid
subcutaneous tumors were generated by inoculating 10
7
ID8-Vegf cells suspended in 250 μl PBS and mixed with
an equal volume of cold Matrigel into the flanks of
mice. Tumors were detectable two weeks later and
tumor size was measured weekly thereafter using a Ver-
nier caliper. Since studies have shown that tumor weight
is the most consistent and reproducible reflection of
tumor volume, especially in small tumors [31], tumor
volumes were calculated by the formula V = ½(L × W)
2,
where L is length (longest dimension) and W is width
(shortest dimension). Experiments were terminated
when control tumors reached the size of 600 to 800
mm
3; all groups were euthanized, the tumors were
excised and weighed.
In vitro treatment of tumor cells
For measurement of chemotherapy sensitivity in vitro,
ID8 tumor cells (1.3 × 10
5/well) were exposed to cyto-
toxic agents for 6 hours in various concentrations:
Topotecan (0, 0.1, 0.3, 1, 3, 10, and 30 μg/ml), paclitaxel
(0, 0.03, 0.1, 0.3, 1, 3, and 10 μg/ml), gemcitabine (0,
0.02, 0.06, 2, 6, 20, and 60 μg/ml), carboplatin(0, 30,
100, 300, 1000, and 3000 μg/ml) and to sodium azide (0,
0.1, 0.3, 1, 3, and 10 μg/ml). At 6 hours the drug con-
taining media was removed, cells were washed twice
with PBS and cultured in drug free media for another
42 hours. Tumor cells were then washed twice with
PBS, thrypsinized and counted. Non-viable cells were
excluded with Trypan Blue staining. For Fas-mediated
killing, we used the anti-Fas agonistic antibody, Jo2
(0.2ug.mL dose, BD PharMingen). Protein G (2 μg/ml;
Biovision) was used to maximize cross-linking of the
primary antibody. The antibody was added 24 hours
before cell harvesting and counting. Control wells
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antibody and protein G. ID8 cell survival fractions after
exposure to different doses of drugs with or without
exposure to Fas agonistic antibody were plotted against
the drug concentrations and the resulting data set was
fit to a logistic dose-response function using Origin7
software (OriginLab Corporation). IC50 values were
obtained from the fit parameters that achieved the low-
est x
2value.
Flow cytometry analysis
Cell surface staining of mouse splenocytes was per-
formed with FITC-labeled anti-CD69 mAb, PE-labeled
anti
_ CD4 mAB, Pe-Cy7-labeled anti-CD3 mAB, PercP-
labeled-anti-CD8 mAb. For the cell surface staining of
ID8 tumor cells anti-MHC-I (H-2Kb/H-2Db) biotiny-
lated mAb and anti-Fas PE-labeled mAb were used. Sec-
ondary Ab was streptavidin-APC labeled. All mAb were
purchased from BD PharMingen. Cell fluorescence was
analyzed and compared with the appropriate isotype-
matched controls (BD PharMingen) with a FACSCanto
cytometer and Flow Jo software.
Apoptosis detection
Detection of apoptotic cells was carried out with the
TACS Annexin V-FITC apoptosis detection system
(R&D Systems) which uses annexinV-fluorescein iso-
thiocyanate (FITC) conjugates for flow cytometry.
Lymphocyte cytotoxicity assay
ID8-E7 cells were prepared for use as targets in a colori-
metric non-radioactive cytotoxicity assay measuring lac-
tate dehydrogenase (Promega). Target cells were
exposed to topotecan or paclitaxel for 6 hours, washed
and cultured for an additional 42 hours. The target cells
(12 × 10
3 cells/well) were coincubated with splenocytes
from vaccinated donor mice (see below) at various effec-
tor:target (E:T) cell ratios, in a final volume of 200 μl
RPMI supplemented with 10% FBS (100 U/ml penicillin
and 100 μg/ml streptomycin) for 4 hours at 37°C with
5% CO2. For the generation of effector cells, eight to
sixteen week old C57BL6 mice were vaccinated twice,
one week apart, with LLO-E7 DNA vaccine [32] encod-
i n gt h eE 7p e p t i d ea n dt h eL i s t e r i aL i s t e r i o l y s i nO
(LLO) adjuvant (kindly provided by Dr. Yvonne Patter-
s o n ) ,a n do n em o n t hl a t e rt h e yw e r ec h a l l e n g e dw i t h5
×1 0
5 TC-1 cells (which express E7) injected s.c in the
flank as boost, which increases significantly the fre-
quency of E7-reactive T cells in the spleen. Two weeks
later, mice were sacrificed, spleens were harvested, sple-
nocytes were isolated and stimulated in vitrof o r7d a y s
with 30 IU/ml IL-2 and 8 μg/ml E7 peptide in RPMI
media (Invitrogen) supplemented with 10% fetal bovine
serum (FBS), 100 U/ml penicillin, and 100 mu μg/ml
streptomycin (Roche) in a 5% CO2 atmosphere at 37°C.
The percent cytotoxicity was calculated with the for-
mula:
% Cytotoxicity =
[Experimental − Effector spontaneous − Target spontaneous] × 100
[Target maximum − Target spontaneous].
Statistical methods
A two-tailed Student’s t-test was used for between-
group comparisons of in vitro and flow cytometry data.
Tumor growth curves depict median and the error bars
interquartile range (25%-75%). Differences were consid-
ered significant at the level of p <0 . 0 5( S t u d e n t ’s test).
The Kaplan-Meier method was used to estimate survival
curves from animal studies. Survival curves were com-
pared with the Wilcoxon statistic.
Results
ID8 tumor cell killing by topotecan and paclitaxel is
phase-dependent
Chemotherapeutic drugs commonly employed against
solid tumors such as ovarian cancer, include carboplatin,
paclitaxel, topotecan and gemcitabine. Among these,
topotecan and paclitaxel are known to be cycle phase-
specific and thus their effect is time- rather than dose-
dependent. The sensitivity of ID8 mouse ovarian cancer
cells to the above drugs was tested in vitro. To mimic
exposure in vivo, where the half life of chemotherapy
drugs is short [33,34], cells were exposed to drug for 6
hours and then were followed for an additional 42
hours. Cell count data at 48 hours were fitted to a logis-
tic regression dose-response curve (Figure 1A). The IC50
- as calculated from these dose response curves - was
used to compare killing curves of the different cytotoxic
agents. ID8 cells were killed by all drugs. A characteris-
tic of phase-specific drugs is that their cytotoxicity
d e p e n d sm a i n l yo nt i m eo fe x p o s u r er a t h e rt h a no n
drug concentration [8,10]. The survival curves of topote-
can and paclitaxel reached a plateau at approximately 5-
fold the IC50, with a substantial fraction of cells surviv-
ing in spite of further dose increase; > 35% of the cells
survived from topotecan and > 20% of cells survived
from paclitaxel. By contrast, gemcitabine and carbopla-
tin exhibited dose-dependent, phase-nonspecific killing
in vitro.
Chemotherapeutic drugs induce MHC and Fas expression
in tumor cells
It has been suggested that cell damage induced by che-
motherapy upregulates the expression of MHC-I or
costimulatory molecules (e.g., NKG2D ligands) in tumor
cells, sensitizes them to Fas or TRAIL mediated apopto-
sis [35-42], and renders them susceptible to immune
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molecules in tumor cells that have sustained lethal
damage from chemotherapy and are destined to die
regardless is unlikely to create a suitable basis for
synergy between chemotherapy and immunotherapy.
Rather, to generate positive interactions, immune effec-
tor mechanisms should be able to target tumor cells
that are able to escape death from chemotherapy.
We examined whether cells that escape death from
time-dependent drugs such as topotecan or paclitaxel
upregulate immune molecules implicated in tumor
immune attack. We measured the expression of MHC-I
and death molecules Fas, TNF-related apoptosis-indu-
cing ligand (TRAIL) and death receptor 6 (DR6) on ID8
cells after short exposure to topotecan or paclitaxel.
Dead cells were identified by propidium iodide and
apoptotic cells by annexin-V binding. Flow cytometry
analysis 42 hrs following exposure to drug showed upre-
gulation of MHC-I and Fas in a subset of viable (propi-
dium iodide-negative and annexin V-negative) ID8 cells
(Figure 1B). The upregulation of both MHC-I and Fas
in viable cells was dose-dependent and was seen at IC50
Figure 1 Topotecan and paclitaxel upregulate MHC-I and Fas on ID8 cells and exert their cytotoxic effects in a phase-specific manner.
(A) Cytotoxic effects of paclitaxel, gemcitabine, topotecan, carboplatin or control sodium azide on ID8 tumor cells. ID8 cells were incubated with
the chemotherapeutic agents for 6 hours. Survival fraction 42 hours later versus concentration (IC50 is used as unit) is shown. Curves are
sigmoidal and for the same time of exposure (6 hours) they plateau at a level that depends on the cell cycle specificity. For topotecan and
paclitaxel the plateau level is > 30% and > 20% respectively, indicating significant phase specificity. For carboplatin and gemcitabine the
sigmoidal curve plateaus at a level < 2.5%. The sigmoidal curves represent the fit of the obtained data to a logistic regression dose response
curve. The killing curve of sodium azide (chemical, no interfering with the cell cycle) was used as a negative control. (B) Upregulation of MHC-I
and Fas on viable ID8 cells treated with topotecan (left) or paclitaxel (right). Cells were exposed to the drugs for 6 hours, washed and incubated
in drug free media for 42 hours before harvesting and staining with MHC-I and Fas antibodies. Isotype control (Red); untreated (Blue); Drug
concentration inducing approximately 50% killing (IC50; Green); Drug concentration corresponding to the plateau of the dose response curve (10
fold IC50; Brown). All the histograms depict Annexin-V negative (non apoptotic) cells. (C) Dot plot diagrams depicting the upregulation of MHCI
and Fas in non-apoptotic tumor cells exposed to Topotecan (upper) and Paclitaxel (lower) at IC50 or 10 fold IC50 for 6 hours 2 days before. (D)
Growth curve of sorted MHC-I positive ID8cells following treatment with topotecan, paclitaxel and carboplatin, as indicated. Error bars represent
interquartile range (25-75%).
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teau of killing curves (Figures 1B, C). The frequency of
non-apoptotic ID8 cells co-expressing MHC-I and Fas
after exposure to drugs at 10-fold IC50 was seven-fold
higher, compared to untreated control cells (27% vs. <
4%, respectively; Figure 1C). Similarly, a fraction of
apoptotic (annexin-V positive) cells also upregulated
MHC-I and Fas after drug exposure (data not shown).
Non-apoptotic ID8 cells did not upregulate expression
of the TRAIL receptor DR5, following exposure to pacli-
taxel or topotecan (not shown). Of note, ID8 cells
exposed to carboplatin or gemcitabine also showed
dose-dependent upregulation of MHC-I and Fas to a
similar degree (not shown). These results show that
short exposure to time-dependent (as well as dose-
dependent) drugs results in a population of tumor cells
that could become potential targets for immune effector
cells.
MHC-I positive tumor cells are capable of re-expanding
following exposure to phase-specific drugs
Next, we examined the fate of tumor cells that upregu-
late MHC-I following short exposure to time-dependent
or dose-dependent drugs. We asked whether these cells
can undergo proliferation and restore tumor mass. ID8
cells were exposed to topotecan, paclitaxel, carboplatin
or gemcitabine at IC70 for 6 hours and were then fol-
lowed in drug-free conditions for 42 hours. Annexin-V
negative, MHC-I positive ID8 cells were purified by
FACS and were plated in normal media for four addi-
tional days. Cells exposed to topotecan proliferated in
vitro and reached a tumor cell number that was
approximately 60% that of a similar starting number of
control ID8 cells that were never exposed to cytotoxic
agents (Figure 1D). Cells exposed to paclitaxel also pro-
liferated in vitro and reached approximately 20% of the
number of control untreated ID8 cells (Figure 1D).
Thus, following primary exposure to time-dependent
drugs, a fraction of annexin-V negative cells that upre-
gulate MHC-I remain viable and maintain their prolif-
erative potential. Similar results were seen with the
annexin-V negative, Fas-positive cells following exposure
to topotecan or paclitaxel (data not shown). In contrast,
annexin-V negative, MHC-I positive ID8 cells treated
with carboplatin (Figure 1D) or gemcitabine at IC70 (not
shown) exhibited no growth in vitro. Similarly, annexin-
V negative, Fas-positive ID8 cells treated with carbopla-
tin or gemcitabine at IC70 exhibited no growth in vitro
(not shown). Collectively, these results indicate that,
although all tested drugs induce a population of tumor
cells that expresses MHC-I and Fas and may be targeted
by immune effector cells, this population remains viable
and is able to restore tumor and thus biologically rele-
vant, only in the case of phase-specific, time-dependent
drugs. We thus hypothesized that combination with
therapy that boosts immune effector cells benefits selec-
tively time-dependent drugs but not dose-dependent
drugs.
Tumor cells surviving topotecan or paclitaxel are
sensitized to effector T cells
To test the above hypothesis, we used as targets ID8-
E6E7 cells, a clonal population of ID8 cells retrovirally
transfected to express HPV 16 E6 and E7 oncogenes
[24]. ID8-E6E7 cells were treated with topotecan or
paclitaxel for 6 hours at IC60 or a dose 10 fold the IC60
and were harvested 42 hrs later to assess their suscept-
ibility to immune-mediated killing. Effector cells reactive
to HPV E7 were expanded from splenocytes of mice
previously vaccinated against HPV E7 using E7 synthetic
peptide. Prior exposure to paclitaxel or topotecan signif-
icantly increased killing of viable ID8-E6E7 cells by sple-
nocytes relative to untreated cells (Figure 2A).
Splenocytes from E7-vaccinated mice did not kill control
ID8 cells that do not express E7, either at baseline or
following exposure to topotecan or paclitaxel (not
shown).
To assess whether chemotherapy-treated, viable
(annexin-V negative) MHC-I positive and Fas-positive
cells are also susceptible to Fas-mediated killing, treated
cells were incubated with Fas agonistic antibody. Again,
cells treated with time-dependent drugs paclitaxel or
topotecan showed increased sensitivity to Fas-induced
death (Figure 2B). We tested whether addition to Fas
agonistic antibody to chemotherapy increased overall
killing of tumor cells. Treatment of ID8 cells with Fas
agonistic antibody in combination with paclitaxel or
topotecan reduced the surviving fraction by nearly 50%
at all concentrations of drug tested (1 to 50 fold the
IC50), but did not improve carboplatin or gemcitabine
treatment at drug concentrations above 10 fold the IC50
(Figure 2C). These results support a significant positive
interaction between Fas ligation and phase-specific che-
motherapeutic drugs.
IL-18 improves the antitumor effect of time-dependent
drugs
Given the above results in vitro,w eh y p o t h e s i z e dt h a t
the addition of IL-18 could selectively increase the effi-
cacy of time-dependent chemotherapeutic drugs such as
topotecan or paclitaxel. First, we tested whether IL-18
exerts a direct cytotoxic effect on ID8 or ID8-Vegf
tumor cells. No direct cytotoxic effect on ID8 or ID8-
Vegf tumor cells was seen in vitro (Figure 3A and not
shown).
Next, we assessed whether IL-18 therapy induces acti-
vation of effector T cells and restricts tumor growth in
mice bearing orthotopic i.p. ID8-Vegf tumors. CD3
+
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+ splenocytes were isolated from mice bearing i.p.
ID8-Vegf tumors and treated with 10 μgo fI L - 1 8d a i l y
for 20 days, starting 10 days following tumor inocula-
tion. A > 2 fold increase in the frequency of CD3
+ CD8
+ splenocytes expressing CD69 (12 ± 1.4% for saline vs.
26 ± 3.2% for IL-18) was seen after 20 days of IL-18
treatment (Figure 3B). Moreover, IL-18 therapy
restricted ascites accumulation, a reliable surrogate of i.
p. tumor growth (p < 0.05, Figure 3C), and prolonged
the survival of ID8-Vegf tumor-bearing mice (p < 0.05;
Figure 3D).
To assess the interactions between IL-18 and time-
dependent drugs, we treated animals bearing i.p. ID8-
Vegf tumors, with paclitaxel at 15 mg/kg (weekly, four
doses), IL-18 (10 μg/day, 40 days), or paclitaxel plus IL-
18. Chemotherapy treatment was started 8 days follow-
ing tumor inoculation and IL-18 treatment was started
2 days later. Control mice were treated with 0.9% saline
alone. Paclitaxel alone prolonged median survival by
39% (57 days) while IL-18 alone prolonged median sur-
vival by 17% (48 days; Figure 4A). In comparison with
paclitaxel monotherapy, the combination of paclitaxel
with IL-18 resulted in significant suppression of ascites
accumulation (p < 0.001) and better survival (p < 0.01),
prolonging median survival by 59% (65 days vs. 41days
in the control group). Survival at 100 days was 0% in
the group treated with paclitaxel; 18% in group treated
with IL-18; and 31% in the group treated with the com-
binatorial therapy; (p < 0.01).
IL-18 administered as above yielded similar results in
combination with topotecan at 2.5 mg/kg (every 5 days,
5 doses) (Figure 4B). The combination of IL-18 with
topotecan prolonged median survival by 35% (58 day; p
< 0.01 relative to topotecan monotherapy), while IL-18
monotherapy prolonged median survival by 14% (49
days) and topotecan alone by 16% (50 days v.4 3d a y si n
the control group; p < 0.01). The combination of IL-18
with topotecan also reduced ascites accumulation com-
pared to topotecan monotherapy (p < 0.001)
IL-18 does not improve the antitumor effect of dose-
dependent drugs
To reveal the significance of time-dependent drug prop-
erties in the interactions between IL-18 and chemother-
apy, we tested the combinations of IL-18 with
carboplatin or gemcitabine, two chemotherapeutic drugs
that kill tumor cells in a dose-dependent manner. Car-
b o p l a t i nw a sg i v e na t2 0m g / k g( w e e k l y ,f o u rd o s e s ) ,
while gemcitabine was given at 25 mg/kg (every 3 days,
5 doses). IL-18 was given as above. Combination of IL-
Figure 2 Tumor cells surviving topotecan or paclitaxel are sensitized to effector T cells. (A) In vitro exposure to paclitaxel or topotecan
enhances the sensitivity of ID8-E6E7 cells to activated E7-specific T cells. Bars show cytotoxicity after exposure to 2 different doses of paclitaxel
and topotecan (IC50 and 10 fold IC50) for the same E:T ratio (20:1). Experiments were performed twice with similar results. (B) Treatment of ID8
cells with topotecan or paclitaxel sensitizes them to Fas agonistic antibody. ID8 cells (untreated or treated with topotecan or paclitaxel at IC50 as
described) were incubated with the Fas agonistic antibody and recombinant protein G or with isotype matched antibody and recombinant
protein G for 24 hours, harvested, stained with trypan blue and the viable cells were counted (hemocytometer). The bars show the mean level
of cytotoxicity and standard errors of three independent experiments. (C) The addition of Fas agonistic antibody to paclitaxel (upper left),
carboplatin (upper right), topotecan (lower left) or gemcitabine (lower right) in vitro targets the resistant ID8 tumor cells and shifts the plateau
phase of the dose-response curve for paclitaxel and topotecan downwards. The sigmoid curves represent the fit of the obtained data to a
logistic regression dose response curve.
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Page 7 of 1218 with carboplatin or with gemcitabine did not
improve the effect of the chemotherapeutic agent alone
either in terms of survival or in terms of ascites accu-
mulation (Figure 4C, D). The median survival in the
group treated with carboplatin alone was identical to
the group that received the combination therapy. Simi-
larly, the median survival afforded by the combination
of IL-18 with gemcitabine was the same as gemcitabine
alone. In both cases, IL-18 monotherapy modestly pro-
longed median survival by 14-15%. There was no signifi-
cant difference in ascites accumulation between the
chemotherapy drugs alone and combination therapy.
These results confirm that in vivo interactions of IL-18
seen with time-dependent chemotherapy drugs are not
seen with dose-dependent drugs.
Positive interactions between IL-18 and phase-specific
chemotherapy drugs are mediated by T cells
Based on the in vitro experiments described above, we
hypothesized that the observed interactions between IL-
18 and time-dependent chemotherapy drugs are
mediated by effector T cells which are activated by IL-18
and attack tumor cells surviving the insult of chemother-
apy. To test this hypothesis, we evaluated the combina-
tion of IL-18 with topotecan in SCID mice lacking T
cells. ID8-Vegf cells were injected s.c. in the flank of
immunocompetent C57BL/6 or SCID mice. Chemother-
apy treatment was started 2 weeks after tumor inocula-
tion, while IL-18 treatment was started 2 days after
initiation of chemotherapy. In C57BL/6 mice, combina-
tion therapy decreased tumor growth relative to control
mice (p < 0.05), while IL-18 or topotecan alone did not
have any significant effect (Figure 5A). The median
tumor weight in the control group was 714 mg (inter-
quartile range 470-1278); in the topotecan group it was
419 mg (325-540, p = 0.06); in the IL-18 group it was
437.5 mg (240-650, p = 0.066); and in the combination
group it was 267 mg (160-360, p = 0.012). In SCID mice,
the effect of combination therapy was lost and there were
no significant differences between the four experimental
arms. The median and interquartile range in the control
group were 631 mg (476-962); in the topotecan group
were 560 mg (392-742, p = 0.4); in the IL-18 group were
463 mg (317-840, p = 0.14); and in the combination
group were 513 mg (292-610, p = 0.13) (Figure 5B).
Discussion
Although chemotherapy is immunosuppressive and tra-
ditional assumption has been that chemotherapy negates
the benefits of immunotherapy in cancer, evidence sup-
porting the notion that chemotherapy can be associated
with immunotherapy is mounting. For example, che-
motherapy can potentially be enhanced by prior vaccine
therapy [43]. However, it has been unclear to date
whether any chemotherapy drugs are more suitable than
others for such chemo-immunotherapy combinations.
Whether chemo-immunotherapy combinations can sig-
nificantly improve the survival benefit obtained with the
conventional treatments is under continuing investiga-
tion, albeit primarily in empirically designed studies
using dose-dependent agents [2,43-48]. Here we charac-
terized the interactions of chemotherapy drugs used
commonly against solid tumors with IL-18, a pleiotropic
immunostimulatory cytokine. We did not provide direct
evidence of phase-selective killing of ID8 cells by the
specific chemotherapeutic drugs in this study, because
the mechanism of killing of these drugs has been widely
documented in the literature so far, including with ovar-
ian cancer cells. For example, in vivo and in vitro stu-
dies with topotecan, an S-phase specific drug,
demonstrated that a high dose given by bolus injection
was less effective than a lower dose given by continuous
exposure [49,50]. Our findings indicate for the first time
to our knowledge that chemotherapy drugs differ in
their ability to interact with immunotherapy, depending
on their mechanism of action. Time-dependent (phase-
Figure 3 IL-18 induces activation of T effector cells, restricts
ascites accumulation and prolongs survival of ID8-Vegf tumor
bearing mice. (A) IL-18 does not have a direct cytotoxic effect on
ID8 tumor cells. ID8 tumor cells (5 × 10
5) were cultured for 48 hours
in media containing IL-18 in a wide range of concentrations (0-1000
ng/ml), harvested, and viable cells counted after staining with
Trypan blue. Results are means ± SEM of 3 experiments. (B) IL-18
induces activation of T effector cells. CD69 expression on CD3
+ CD8
+ cells isolated from the spleen of ID8-Vegf tumor bearing mice
treated with saline or IL-18 (10 μg/day s.c for 20 days, starting 10
days after the tumor challenge). The bars are mean ± SEM of the
CD69 expression in CD3
+ CD8
+ cells from spleens of 5 mice treated
with IL-18 as above and 5 mice treated with saline. (C) Antitumor
properties of IL-18 in C57BL/6 mice. IL-18 significantly restricts
ascites accumulation as depicted by increase in the animal weight.
The asterisks show data points were the difference between the
groups is significant (Student’s test, P < 0.05). (D) IL-18 significantly
prolongs the survival of ID8-Vegf tumor bearing mice (P < 0.05).
Control n = 9, IL-18 treated n = 9.
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Page 8 of 12specific) agents, such as topotecan or paclitaxel exhib-
ited positive interactions with immunotherapy in vivo
while dose-dependent (phase-nonspecific) drugs did not.
Time-dependent drugs target tumor cells in vulnerable
phases of the cell cycle, and the fraction of tumor cells
killed depends mainly on time of exposure rather than
on drug dose [8,10]. Given that the time of in vivo expo-
sure to chemotherapy drugs administered in conven-
tional formulations is limited by their short half-life
[35,36], a large fraction of tumor cells takes up drug but
survives the insult. Our in vitro studies indicate that
although these cells remain viable and can reconstitute
the tumor, chemotherapy exposes a novel “Achilles’ hill”
on them. The fraction of viable tumor cells surviving
time-dependent chemotherapy exposure showed
increased expression of MHC-I and Fas and increased
sensitivity to cytotoxic lymphocytes and Fas agonistic
antibody. Although MHC-I and Fas were upregulated
also in tumor cells treated with phase-nonspecific drugs
such as carboplatin and gemcitabine, these cells were all
apoptotic and had no tumorigenic potential. The central
role of the immune system, particularly effector T cells,
in expanding the efficacy of time-dependent chemother-
apy was confirmed by the abrogation of the IL-18 and
topotecan interaction in tumor-bearing SCID mice
lacking T cells. We cannot exclude contribution of
other effector cell types, but we expect T cells to be a
significant part of the positive interactions between
phase-specific chemotherapy drugs and IL-18 in vivo in
the mouse and in the human. Thus, an intact immune
system is required to observe the therapeutic effects of
topotecan and our studies provide novel insights in the
complex interactions between chemotherapy and
immune therapy. Although the notion that chemother-
apy upregulates MHC-I and Fas on tumor cells is not
novel, the notion that this becomes biologically and
clinically relevant particularly for phase-specific drugs is
novel and generates new opportunities for the rational
design of chemo-immunotherapy combinations.
In this study we specifically focused on whether, and
which, chemotherapy agents sensitize tumor cells to
immune effector mechanisms; we thus tried to mainly
explore the ability of drugs to render tumor cells more
susceptible to immunotherapy with IL-18, and did not
investigate each drug’so v e r a l le f f e c t so nt h ei m m u n e
system. Additional interactions are possible between
chemotherapy and immune therapy. Cytotoxic drugs,
when combined with immunotherapy, have the potential
to provide a variety of agonistic effects to overcome the
multiple barriers to natural antitumor responses. First,
Figure 4 IL-18 improves only the antitumor effect of time-dependent drugs. (A) Combination therapy with IL-18 improves the survival
benefit offered by paclitaxel and topotecan alone and restricts ascites accumulation (left). C57BL/6 mice were injected i.p. with 5 × 10
6 ID8-Vegf
cells on day 0 and subsequently treated with the indicated types of treatment. Mice treated with the combination of paclitaxel plus IL-18 had a
significantly prolonged survival compared to the respective monotherapies (p < 0.01; control n = 23, IL-18 alone n = 22, paclitaxel n = 14, IL-18
plus paclitaxel n = 13). Combination therapy significantly restricted ascites accumulation (right) compared to the respective monotherapies as
measured by the increase in the animal weight. The asterisks show data points where the difference in ascites accumulation is significant
(Student’s test, P < 0.001). (B) The combination of topotecan plus IL-18 also significantly prolonged the survival comparing to the respective
monotherapies (p < 0.01; control n = 10, IL-18 alone n = 10, topotecan alone n = 9, IL-18 plus paclitaxel n = 10). Combination therapy
significantly restricted ascites accumulation (right). The addition of IL-18 to carboplatin (C) or gemcitabine (D) did not significantly improve
survival (left) or restrict ascites accumulation (right). IL-18/carboplatin experiment: Control n = 9, IL-18 n = 9, carboplatin n = 9, IL-18 plus
carboplatin n = 9. IL-18/gemcitabine experiment: Control n = 10, IL-18 n = 10, gemcitabine n = 9, IL-18 plus gemcitabine n = 10.
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Page 9 of 12chemotherapy can diminish the impact of tumor immu-
noregulatory factors by reducing tumor burden. For
example, during monitoring of T cell responses to anti-
genic epitopes of cytomegalovirus, EBV, and influenza in
advanced ovarian carcinoma patients, it was found that
CD8
+ T cell responses were significantly lower in
patients with high levels o fC A 1 2 5t h a ni nt h o s ew i t h
low CA125 levels. Furthermore prospective monitoring
before, during, and after first-line carboplatin/paclitaxel
chemotherapy revealed that CD8
+ T cell responses were
restored by chemotherapy but only in patients in remis-
sion, while patients with progressive disease did not
show improvement of CD8
+ T cell responses [51]. In
addition, chemotherapy can directly eliminate immuno-
suppressive cells such as regulatory T cells and/or mye-
loid suppressor cells; deplete host cells that compete
with tumor antigen-specific T cells for homeostatic
cytokines required for T cell proliferation and survival;
and/or promote robust activation of professional antigen
presenting cells [52]. Further, cytotoxic agents can
modify the tumor microenvironment to favor anti-
tumor responses through the promotion of tumor anti-
gen processing and presentation, increased antigen
uptake and improved homing of immune cells to tumor
[53]. Specifically for gemcitabine, in addition to its apop-
totic effects, it promotes the cell-mediated immune
response over the humoral immune response by selec-
tively inhibiting B-cell proliferation [54], decreasing
memory T cells, and promoting the activation of naive
T cells [55] and function of CD8+ T cells [56]. Immu-
nopotentiation is also achieved in part by the inhibitory
effects of gemcitabine on myeloid-derived suppressor
cells [57]. These mechanisms were recently reviewed by
us [58]. Lastly, chemotherapy can induce anti-angiogenic
effects [59-61], which could potentially further enhance
T cell homing to tumors.
Chemotherapy in ovarian cancer patients has been
shown to temporarily reverse immunosuppression, and
decrease the proportion of regulatory T cells. Likewise,
it increases the percentage of IFN-g secreting CD8
+ cells
12-14 days after administration, thus offering a “win-
dow” period for the use of immunotherapy, maximizing
the tumor killing effect of both modalities [62]. On the
other hand, simultaneous administration of immu-
notherapy combined with standard chemotherapy, could
also be beneficial to ovarian cancer patients and better
than a week-delayed schedule [63]. Thereby, not only
t h ec h o i c eo ft h ea c t i v ed r u gb u ta l s ot h et i m i n go f
immunotherapy is crucial for optimal results and this
should be elucidated in future studies. The observed
lack of interaction of gemcitabine with IL-18 in this
study could be attributed, not only to the drug’s
mechanism of action, but also to the specific pharmaco-
logic properties of IL-18. Our results could be affected
by the relative sensitivity of tumor cells to each che-
motherapy drug, and tumors with increased sensitivity
could show different interactions. However, increased
sensitivity to the chemotherapy drug does not necessa-
rily mean that interactions with IL-18 would be more
pronounced. Similarly, reduced sensitivity to the drug
should not preclude interactions to be seen.
Conclusions
Our results support the concept that immunotherapy
can be used to increase the killing effect of chemother-
apy. Tumor immunotherapy with IL-18 can significantly
augment the killing fraction of phase-specific che-
motherapeutic drugs and provide survival benefit. Given
that phase specificity is an inherent characteristic of sev-
eral chemotherapeutic drugs used in a variety of cancers
and a major factor that leads to treatment failures, the
potential use of immunotherapy as a means to increase
the killing fraction of phase dependent drugs, especially
in tumors with low mitotic fraction, needs clinical
Figure 5 The antitumor effect of combination IL-18/
chemotherapy is T cell dependent. C57BL/6 (A) or C57SCID (B)
mice were injected s.c. in the flank with ID8-Vegf cells and
subsequently treated as described in “Materials and Methods.” Mice
with no treatment, topotecan alone, IL-18 alone or their
combination were sacrificed when control tumors reached a size of
approximately 600 to 800 mm
3 ; all tumors were excised and
weighed. Results are medians ± SEM: interquartile range (25%-75%;
n = 10). The asterisk indicates the statistically significant difference
between experimental and control groups. In the C57BL/6 mice, the
topotecan/IL-18 combination treatment significantly restricted the
tumor weight relative to the control group (Student’s test, p < 0.05),
while independent monotherapies did not. In the SCID mice the
effect of the combinatorial therapy on the tumor growth was lost
with no significant differences between the groups.
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Page 10 of 12testing. The safety profile of IL-18 and its positive inter-
actions with select anticancer chemotherapeutic agents
strongly supports the clinical investigation of this com-
binatorial approach. Additionally, in order to improve
the positive interaction effect of IL-18 and phase-specific
chemotherapeutic drugs, different dosing schedules and
ways of drug delivery (e.g. liposomal formulations, pro-
tein-bound particles, or nanoparticles) should be used in
future studies.
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